Polycythaemia vera and essential thrombocythaemia: Current treatment strategies

Drugs

Volumn 66, Issue 17, 2006, Pages 2173-2187

  Penninga, Elisabeth I ^a   Bjerrum, Ole W ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; BUSULFAN; CAPTOPRIL; CORTICOSTEROID; DANAZOL; ENALAPRIL; GINKGO BILOBA EXTRACT; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; IBUPROFEN; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHOSPHORUS 32; PIPOBROMAN; PROBENECID; PROTON PUMP INHIBITOR; SUCRALFATE;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BLEEDING; CELERY; CLINICAL FEATURE; DANDELION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA; FEVER; FLUID RETENTION; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEART PALPITATION; HUMAN; HYPERPIGMENTATION; HYPERURICEMIA; INJECTION SITE REACTION; LEG ULCER; LEUKEMOGENESIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MENTAL HEALTH; MOUTH ULCER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PHLEBOTOMY; POLYCYTHEMIA VERA; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SCLEROMYXEDEMA; SIDE EFFECT; STOMACH IRRITATION; STOMATITIS; TACHYCARDIA; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

HUMANS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 33845349641     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666170-00003     Document Type: Review

References (96)

1. Bench AJ, Cross NCP, Huntly BJP, et al. Myeloproliferative disorders. Clin Haematol 2001; 14: 531-51
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90
3. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000; 95: 2569-76
4. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709-15
5. Barbui T, Finazzi G. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Curr Hematol Rep 2003; 2: 248-56
6. Chintagumpala MM, Steuber CP, Mahoney DH, et al. Essential thrombocythemia in a child: management with anagrelide. Am J Pediatr Hematol Oncol 1991; 13: 52-6
7. Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr 1995; 127: 495-8
8. Hermann J, Collins MH, D'Angio GJ. Successful treatment of essential thrombocythemia with anagrelide in a child. Med Pediatr Oncol 1998; 30: 367-71
9. Lackner H, Urban C, Beham-Schmid C, et al. Treatment of children with anagrelide for thrombocythemia. J Pediatr Hematol Oncol 1998; 20: 469-73
10. Tefferi A. Current management of polycythemia vera. Leuk Lymphoma 2002; 43: 1-7
11. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001; 49: 164-6
12. Fenaux P, Dimon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-56
13. Jensen MK, de Nully Brown P, Nielsen OJ. Incidence, clinical features and outcome of essential thrombocythemia in a well defined geographical area. Eur J Haematol 2000; 65: 132-9
14. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycytemia vera and essential thrombocythemia. Am J Med 2000; 109: 141-9
15. Van Genderen PJJ, Troost MM. Polycythemia vera and essential thrombocythemia in elderly. Drugs Aging 2000; 17: 107-19
16. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002; 76: 133-45
17. Green AR, Vassiliou GS, Curtin N, et al. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 2004; 5: 126-32
18. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol 2002; 76 Suppl. 2: 193-203
19. Pearson TC, Messinezy M, Westwood N, et al. A polycythemia vera update: diagnosis, pathobiology and treatment. In: Hematology 2000, the American Society of Hematology Education Book. Washington, DC: American Society of Hematology, 2000: 51-68
20. Tefferi A. A contemporary approach to the diagnosis and management of polycythemia vera. Curr Hematol Rep 2003; 2: 237-41
21. Spivak JL. Polycythemia vera: myths, mechanisms and management. Blood 2002; 100: 4272-90
22. Gilbert HS. Modern treatment strategies in polycythemia vera. Semin Hematol 2003; 40: 26-9
23. McMullin MF, Barefod D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174-95
24. Spivak JL. The optimal management of polycythemia vera. Br J Haematol 2002; 116: 243-54
25. Osler W. Chronic cyanosis with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 126: 187-201
26. Berlin NI. Diagnosis and classification of the polycytemias. Semin Hemattol 1975; 12: 339-51
27. Andreasson B, Lofvenberg E, Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol 2005; 74: 489-95
28. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycytemia vera: evaluation of performance and practical utility. Cancer 2005; 104: 213-5
29. Jaffe ES, Harris NL, Stein H. World Health Organization Classification of tumours: pathology and genetics of tumours of haematopoietic and plymphoid tissues. Lyon: IARC Press, 2001
30. Cazzola M, Skoda R. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders. Haematologica 2005; 90: 871-4
31. Michiels JJ, de Raeve H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic meyloproliferative disorders. Semin Thromb Hemost 2006; 32: 307-40
32. Tefferi A. The diagnosis of polycythemia vera: new tests and old dictums. Best Pract Res Clin Haematol 2006; 19: 455-69
33. Villeval J-L, James C, Pisani DF, et al. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost 2006; 32: 341-51
34. Gilbert HS. Current management in polycythemia vera. Semin Hematol 2001; 38: 25-8
35. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24
36. Gilbert HS. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol 2006; 36 (1 Suppl. 2): 19-22
37. Harrison CN. Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 2005; 130: 153-65
38. Van Genderen PJJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993; 67: 57-62
39. Briere J, Guilmion F. Management of patients with essential thrombocythemia: current concepts and perspectives. Pathol Biol (Paris) 2001; 49: 178-83
40. Dugan V, Higginbotham R, Gilbert J, et al. Essential thrombocytosis: diagnostic and treatment dilemmas. J La State Med Soc 2003; 155: 306-13
41. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-32
42. McMullin MF, Bareford D, Craig J, et al. The optimal management of polycythemia vera. Br J Haematol 2003; 120: 543-4
43. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N Engl J Med 1995; 332: 1132-6
44. Löfvenberg E, Wahlin A. Management of polycythemia vera, essential thrombocytosis and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375-81
45. Olesen LH, Pedersen BB. Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders. Ugeskr Laeger 2001; 163: 6908-11
46. Lengfelder E, Berger U, Hehlmann R. Interferon-alpha in the treatment of polycythemia vera. Ann Hematol 2000; 79: 103-9
47. Lengfelder E, Grisshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996; 22: 135-42
48. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487), a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98: 100-9
49. Samuelsson J, Hasselbalch HC, Bruserud O, et al. A phase II trial of pegylated inteferon alfa-2b therapy for polycythemia vera and essential thrombocythemia. Cancer 2006; 106: 2397-405
50. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006 Sep 15; 108 (6): 2037-40
51. Samuelsson J, Mutschler M, Birgegard G, et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006 Sep; 91 (9): 1281-2
52. Silver RT. Imatinib mesylate (Gleevec (™) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003; 17: 1186-7
53. Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk Res 2001; 25: 369-77
54. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis and management. Blood Rev 2001; 15: 121-31
55. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003; 82: 148-52
56. Barbui T, Finazzi G, Dupuy E, et al. Treatment strategies in essential thrombocythemia a critical appraisal of various experiences in different centers. Leuk Lymphoma 1996; 22: 149-60
57. Campbell PJ, Scott LM, Wheathley K, et al. Definition of subtypes of essential thrombocythaemia and relation to polycytaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-53
58. Barbui T. Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003; 40: 22-5
59. Barbui T. What is the standard treatment in essential thrombocythemia. Int J Hematol 2002; 76 Suppl. 2: 311-7
60. Gisslinger H. Update on diagnosis and management of essential thrombocythemia. Semin Thromb Hemost 2006; 32: 430-6
61. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350: 1211-9
62. Michiels JJ, Berneman Z, van Bockstaele D, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174-207
63. Penninga EI, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004; 26: 335-40
64. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97: 863-6
65. Van Genderen PJJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179-84
66. Nand S, Stock W, Godwin J, et al. Leukemogenic risk of hydroxyurea therapy in polycytemia vera, essential thrombocytosis and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52: 42-6
67. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocytosis treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-22
68. Tatarsky I, Sharon R. Management of polycytemia vera with hydroxyurea. Semin Hematol 1997; 34: 24-8
69. Weinfeld A, Swolin J. Acute leukemia after hydroxyurea treatment in polycytemia vera and allied disorders: prospective study of efficacy and leukemogenicity with therapeutic implications. Eur J Haematol 1994; 52: 134-9
70. Lõfvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea treated patients with Philadelphia chromosome negative diseases. Cancer Genet Cytogenet 1990; 49: 57-67
71. Haft VN, Fruchtman SM, Pickens CV, et al. DNA mutating associated with in vivo hydroxyurea-exposure. Blood 2000; 95: 3589-93
72. Halsey C, Roberts IA. The role of hydroxyura in sickel cell disease. Br J Haematol 2003; 120: 177-86
73. Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577-83
74. Murphy S, Peterson P, Iland H, et al. Experience of the Polycytemia Vera Study Group with essential thrombocytosis: a final report on diagnostic criteria, survival and leukemic transformation by treatment. Semin Hematol 1997; 34: 29-39
75. Anagrelide Study Group. Anagrelide, a novel therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69-76
76. Brooks WG, Standley DD, Goode JV. Role of anagrelide in the treatment of thrombocytosis. Ann Pharmacother 1999; 33: 1116-8
77. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 1998; 55: 1979-86
78. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experiences in 48 patientes in Germany. Eur J Haematol 1998; 61: 71-6
79. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006; 66: 111-31
80. Birgegaard G. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 260-6
81. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycytemia and other myeloproliferative disorders. Semin Hematol 1997; 34: 51-4
82. Silverstein MN, Petitt RM, Solberg LA, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 1292-4
83. Knutsen H, Hyssing J. Anagrelid ved primær trombocytemi. Tidsskr Nor Laegeforen 2001; 121: 1478-82
84. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999; 36 (1 Suppl. 2): 23-5
85. Birgegård G, Björkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004; 89: 520-7
86. Steurer M, Gastl G, Jedrzejczak W-W, et al. Anagrelide for thrombocytosis in myeloproliferative disorders. Cancer 2004; 101: 2239-46
87. Harrison CN, Path MR, Campbell PJ, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45
88. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005; 353: 85-6
89. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003; 51: 81-6
90. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythemia: experiment with 40 pregnancies. Eur J Haematol 2004; 73: 431-6
91. Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. Acta Haematol 2002; 107: 158-69
92. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293-306
93. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia / Polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32: 422-9
94. Doubek M, Brychtova Y, Doubek R, et al. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. Ann Hematol 2004; 83: 726-7
95. Byrd DC, Pitts SR, Alexander CK. Hydroxyurea in two pregnant women with sickle cell anemia. Pharmacotherapy 1999; 19: 1459-62
96. Pata O, Tok CE, Yazici G, et al. Polycythemia vera and pregnancy: a case report with the use of hydroxyurea in the first trimester. Am J Perinatol 2004; 21: 135-7